Addressing the unmet needs of immunocompromised individuals seeking COVID-19 protection – EVUSHELD TM overview and resources

Nellie Byun, Ph.D. and Derek Eisnor, M.D.

Biomedical Advanced Research and Development Authority (BARDA), in the HHS Office of the Assistant Secretary for Preparedness and Response.

COVID-19 restrictions are lifting across the U.S. driven by decreasing hospitalization rates. Despite this welcomed return to normalcy for most people in the United States, immunocompromised individuals still suffer higher risks of hospitalization and death from COVID-19.1,2 This is due, in large part, to a reduced response to currently authorized vaccines. Despite recommended vaccination and boosting, immunocompromised individuals are still at risk for severe COVID-19 and need added protection.

The U.S. government has been working to supply additional COVID-19 therapies for the approximately 7 million highest risk, immunocompromised Americans.3 The success of both preventive and treatment therapeutics is based on public and healthcare provider education and awareness. Increased access is the first part of the equation. Here are four updates that you should know on the current landscape of COVID-19 prevention for immunocompromised individuals.

Click here for more Information About Evusheld